PBLS (Parabilis Medicines) Preferred Dividends: $41.04 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.43
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines Preferred Dividends?

Parabilis Medicines PBLS -4.21% 10 Preferred Dividends is $41.04 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Parabilis Medicines's preferred dividends for the six months ended in Dec. 2025 was $41.04 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $41.04 Mil.

Parabilis Medicines  (NAS:PBLS) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $41.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Preferred Dividends Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Preferred Dividends Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Preferred Dividends
43.57 41.04

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Preferred Dividends 43.57 41.04
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $41.04 Mil mean?
Parabilis Medicines (PBLS) has a Preferred Dividends of $41.04 Mil as of Dec. 2025. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Parabilis Medicines and its competitors.
Is Parabilis Medicines' Preferred Dividends too high?
Parabilis Medicines' current Preferred Dividends is $41.04 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Preferred Dividends compare to IDYA and ELVN?
Parabilis Medicines' Preferred Dividends of $41.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Preferred Dividends is $41.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Preferred Dividends of $41.04 Mil. The current Preferred Dividends is $41.04 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Preferred Dividends is $41.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.43
Price